# US 7,608,612 B2 · Radiosensitizer formulations and methods for use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,612 B2
- Document ID: US7608612B2
- Status: Granted
- Kind: B2
- Application number: 11/336,419
- Filed: 2006-01-20
- Published: 2006-08-31
- Granted: 2009-10-27
- Earliest claimed: 2005-01-21
- Assignees: Richard H. Matthews
- Inventors: Richard H. Matthews; Nuran Ercal; Robert Zand
- Web page: https://patentgrep.com/patent/US7608612B2

## CPC

- A61K 31/4172: Imidazole-alkanecarboxylic acids, e.g. histidine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents that provide a synergistic radiosensitizing effect. Methods of potentiating radiotherapy cancer treatment of cancers in humans, particularly of astrocytomas, are also presented, wherein a radiosensitizer composition is administered and radiotherapy is directed to the site of the tumor. Chemotherapy regimens may also be used as adjuvant therapy.

## Claims

### Claim 1

A method of potentiating radiotherapy cancer treatment comprising:
administering to a patient in need thereof a therapeutically effective amount of a composition comprising a radiosensitizer of formula (I)
wherein R1 is H; and
directing radiotherapy at a prescribed dosage to a locus of cancer,
wherein the cancer is a small cell lung carcinoma or a non small cell lung carcinoma.

### Claim 2 (depends on 1)

A method of potentiating radiotherapy cancer treatment according to claim 1, wherein the composition further comprises one or more agents.

### Claim 3 (depends on 2)

A method of potentiating radiotherapy cancer treatment according to claim 2, wherein the one or more agents is buthionine sulfoximine, a nitrosourea agent, N-(phosphonylacetyl)-L-aspartic acid (PALA), a chemotherapeutic agent, or any combination thereof.

### Claim 4 (depends on 1)

A method of potentiating radiotherapy cancer treatment according to claim 1, further comprising, administering daily doses of the radiosensitizer throughout the course of treatment.